PDGFR alpha (CD140a/PDGFRA) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 29 Jul 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for GIST, Glioma, Fibrosis, and Systemic Mastocytosis Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for PDGFR alpha drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen (WT & Mutant) PDGFR alpha ECD-Fc / Mutant Kinase Domain Protein
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Includes WT, D842V, V561D mutants. HEK293 expressed for native glycosylation.		 View PDGFR alpha Products
Gene Delivery PDGFR alpha Lentivirus Premade Particles
Full-length ORF for stable cell lines. HEK293T packaged, titer >10^8 TU/mL. Preserves native membrane conformation.		 View PDGFR alpha Products
Benchmark Ab Anti-PDGFR alpha Recombinant Antibody (Sequence of Olaratumab biosimilar)
Sequence-verified positive control for binding assays.		 View PDGFR alpha Products
Validator PDGFR alpha siRNA Set (3 unique sequences)
For knockdown specificity verification and rational design validation.		 View PDGFR alpha Products
Related Target: PDGFR beta CD140b (PDGFRβ)
Heterodimerization partner; crucial for counter-screening and bispecific development.		 View PDGFR beta Products
Related Target: KIT CD117 (c-KIT)
Parallel pathway in GIST; combination therapy target. Also essential for selectivity profiling against Type III RTK family.		 View KIT Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Resistance Mutation Profiling (D842V, V561D) Purified WT, D842V, and V561D mutant proteins (ECD-Fc or kinase domain); sequence verified by mass spec.
Subfamily Counter Screening (Selectivity) Homolog panel: PDGFRβ, KIT, FLT3, CSF1R proteins (>95% purity) for SPR/BLI cross-reactivity assays.
Cross-species Translation Human/Mouse/Cynomolgus PDGFR alpha ECD proteins (>95% purity) for preclinical immunogenicity assessment.
ADC Internalization Validation ECD-Fc fusion preserves native glycosylation (HEK293 expressed) for accurate internalization kinetics.
Lack of Controls / False Positives Clinical benchmark antibodies (biosimilars) and validated siRNA included for assay standardization and specificity checks.

Live PDGFR alpha R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for PDGFR alpha therapeutics is intensifying. Major players are shifting focus from traditional tyrosine kinase inhibitors (TKIs) to next-generation modalities: antibody-drug conjugates (ADCs), bispecific antibodies, ligand-trapping biologics, and targeted degradation (PROTACs). First-generation TKIs (imatinib, sunitinib) face escalating resistance mutations—particularly the D842V gatekeeper mutation in GIST. The next wave of R&D targets allosteric inhibitors, mutant-selective TKIs, and degradation strategies to overcome refractory mutations (V561D, V658A, N659K).

Key therapeutic domains include:

  • Gastrointestinal Stromal Tumors (GIST): PDGFRA mutations define 5-10% of cases; D842V is imatinib-resistant but avapritinib-sensitive.
  • Glioblastoma: Autocrine PDGFRA signaling loops drive tumor growth.
  • Idiopathic Pulmonary Fibrosis (IPF): PDGFRα drives myofibroblast activation.
  • Systemic Mastocytosis & Hypereosinophilic Syndrome: Driven by FIP1L1-PDGFRA fusions and other activating mutations.
  • Other Fibrotic Diseases: Pulmonary arterial hypertension (PAH) and neovascular eye diseases via local administration (inhaled or intravitreal).

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Type I/II TKI Blueprint Medicines, Deciphera, Novartis GIST (D842V+), Systemic Mastocytosis Mutant vs WT protein panel (D842V, V561D, V658A); selectivity against KIT, PDGFRβ
ADC Daiichi Sankyo, LegoChem Biosciences Solid Tumors (Glioma, GIST) Internalization assay (high-purity ECD-Fc with native glycosylation)
Bispecific Antibody CSL Behring, Innovent Fibrosis (IPF) Heterodimer validation (PDGFRα/β cross-reactive Abs); ligand competition assays
Ligand Trap Novartis (early) Fibrosis Ligand binding affinity (PDGF-AA/BB competition)
Monoclonal Antibody Eli Lilly (historical) Sarcoma, Solid Tumors SPR/BLI binding assays (HEK293 expressed ECD-Fc)
PROTAC / Degradation Emerging Biotech Refractory Cancers Mutant vs WT kinase domain proteins for ternary complex assays